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Abstract
The risk of acute graft-versus-host disease (GVHD) after HLA-matched sibling bone marrow 
(BM) transplantation is lower in Japanese than in Caucasian patients. However, race may have 
differential effect on GVHD dependent on the graft source. North American Caucasian and 
Japanese patients receiving their first allogeneic BM or peripheral blood stem cell (PBSC) 
transplantations from an HLA-matched sibling for leukemia were eligible. BM was used in 13% 
and 53% of Caucasian and Japanese patients, respectively. In multivariate analysis, the interaction 
term between race and graft source was not significant in any of the models, indicating that graft 
source does not affect the impact of race on outcomes. The risk of grades III–IV acute GVHD was 
significantly lower in Japanese than in Caucasian patients (hazard ratio (HR) 0.74, 95% 
confidence interval (CI) 0.57–0.96), which resulted in lower risk of non-relapse mortality in 
Japanese patients (HR 0.69, 95% CI 0.54–0.89). The risk of relapse was also lower in this group. 
Lower risk of non-relapse mortality and relapse resulted in lower overall mortality rates among 
Japanese patients. In conclusion, irrespective of graft source, the risk of severe acute GVHD is 
lower in Japanese patients, which results in lower risk of non-relapse mortality.
Keywords
graft-versus-host disease; bone marrow transplantation; peripheral blood stem cell transplantation; 
race
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Several studies have demonstrated lower acute graft-versus-host disease (GVHD) risks after 
human leukocyte antigen (HLA)-matched sibling bone marrow transplantation (BMT) 
among Japanese, a genetically homogeneous population, compared to Caucasian and other 
races.[1,2] The lower incidence of acute GVHD was likely due to the relative homogeneity 
of minor histocompatibility antigens among Japanese.[3,4] Understanding outcome 
differences among races is particularly important for interpretation of transplant study 
findings and application of these results to clinical practice. In recent years, despite evidence 
of slightly increased risk of GVHD, peripheral blood stem cells (PBSC) have been more 
frequently used than bone marrow (BM) as stem cell grafts because of earlier neutrophil and 
platelet engraftment, perceived better overall survival in advanced or high-risk diseases,[5] 
and easier collection procedure. The effect of race may differ according to stem cell sources, 
because the number and subpopulations of T and other immune cells responsible for GVHD 
differ significantly between BM and PBSC.[6,7] To our knowledge, no other reports have 
assessed outcome differences between races after HLA-matched sibling PBSC 
transplantation (PBSCT).
Several groups in Europe and the U.S. have conducted randomized controlled trials 
comparing HLA-matched sibling BMT and PBSCT.[8–11] Based on these randomized 
studies, the Stem Cell Trialists’ Collaborative Group conducted an individual-patient data 
meta-analysis using combined data from 1,111 adult patients.[5] The incidence of grades 
III–IV acute GVHD was 26% and 21% in the HLA-matched sibling PBSCT and BMT 
groups, respectively, with an odds ratio of 1.39 (95% confidence interval [CI], 1.03–1.88). 
Regarding matched unrelated donor transplantation, Anasetti et al. recently compared 
outcomes of unrelated donor BMT and PBSCT in a large multicenter randomized trial.[12] 
They reported a similar incidence of acute GVHD among BMT and PBSCT recipients. 
Nagafuji et al. retrospectively evaluated outcomes after HLA-matched sibling BMT and 
PBSCT in Japan using Japanese national registry data.[13] In this study, the incidence of 
grades III–IV acute GVHD was 14% and 5% in the HLA-matched sibling PBSCT and 
BMT, respectively, with a hazards ratio of 2.23 (95% CI, 1.04–4.78). These reports suggest 
that the incidence of severe acute GVHD was very low after HLA-matched sibling BMT in 
the Japanese population and the risk ratio of severe acute GVHD in PBSCT vs. BMT was 
much larger in Japanese than in Caucasian and other populations (2.23 vs. 1.39). In this 
context, we hypothesized that the lower incidence of acute GVHD in Japanese compared to 
Caucasian populations observed in HLA-matched sibling BMT will not be detectable in 
HLA-matched sibling PBSCT, and that there is an interaction between race and use of BM 
or PBSC. Furthermore, we hypothesized that this difference in severe acute GVHD rates 
between the races will affect other transplant outcomes and choice of BM or PBSC in HLA-
matched sibling transplantation. Therefore, we accessed the large registry data of the Center 
for International Blood and Marrow Transplant Research (CIBMTR) and the Japan Society 
of Hematopoietic Cell Transplantation (JSHCT) to compare transplant outcomes between 
Japanese and Caucasian patients who received BMT or PBSCT from an HLA-matched 
sibling.
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Data were obtained from the CIBMTR and the Transplant Registry Unified Management 
Program (TRUMP) of JSHCT for U.S. and Japanese transplants, respectively.[14] The 
CIBMTR is a combined research program of the Medical College of Wisconsin and the 
National Marrow Donor Program. The CIBMTR comprises a voluntary network of more 
than 500 transplantation centers worldwide, which contribute detailed data on consecutive 
allogeneic and autologous hematopoietic cell transplantation to a centralized statistical 
center. Observational studies conducted by the CIBMTR are performed in compliance with 
all applicable U.S. federal regulations pertaining to the protection of human research 
participants. Protected health information used in the performance of such research is 
collected and maintained in the CIBMTR capacity as a public health authority under the 
Health Insurance Portability and Accountability Act Privacy Rule. Additional details 
regarding the data source are described elsewhere.[15] JSHCT developed the TRUMP to 
enable transplant centers to manage patient information with emphases on convenience to 
centers, safety of patient information, and quality of data management. TRUMP unifies data 
of 4 Japanese registries; JSHCT, Japanese Society of Pediatric Hematology, Japan Marrow 
Donor Program, and Japan Cord Blood Bank Network. Adult related allogeneic 
transplantations performed in Japan are registered through JSHCT.[14] Registration of the 
JSHCT does not require patient consent because clinical information is anonymized. The 
study was approved by the Institutional Review Board of the National Marrow Donor 
Program, Medical College of Wisconsin, Saitama Medical Center, Jichi Medical University, 
and the Data Management Committees of the JSHCT.
Inclusion criteria and data preparation
North American Caucasian and Japanese patients who received their first allogeneic BMT or 
PBSCT from an HLA-matched sibling for acute myelogenous leukemia (AML) and acute 
lymphoblastic leukemia (ALL) in first and second complete remission or chronic 
myelogenous leukemia (CML) in complete remission or chronic or accelerated phase 
between 2000 and 2011 were eligible. Patients were 18–59 years of age, received a 
myeloablative conditioning regimen, and used cyclosporine or tacrolimus-based GVHD 
prophylaxis. Patients with use of in vivo or ex vivo T cell depletion methods were excluded. 
AML or ALL in first complete remission and CML in first chronic phase or complete 
remission were defined as early risk disease. AML or ALL in the second complete remission 
and CML in the second or higher chronic phase or accelerated phase were defined as 
intermediate risk disease. Eastern Cooperative Oncology Group performance statuses of 0 
and 1 or more were converted to Karnofsky performance status (KPS) 90–100 and <90, 
respectively, for patients in the Japanese dataset lacking KPS scores, following a conversion 
formula used in the CIBMTR. In the CIBMTR registration forms, race is categorized into 
“White or Caucasian”, “Black or African American”, “American Indian or Alaska Native”, 
“Asian”, and “Native Hawaiian or other Pacific Islander”. North American Caucasian 
includes Caucasians who live in the U.S., Canada, and Mexico.
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Outcomes assessed include acute GVHD, chronic GVHD, relapse, non-relapse mortality, 
leukemia-free survival, and overall survival. Acute and chronic GVHDs were diagnosed and 
graded using the traditional criteria.[16,17] Non-relapse mortality was defined as death 
without relapse. Leukemia-free survival was defined as being alive in remission. For overall 
survival, death from any cause was the event.
Statistical analysis
Patient-, disease-, and transplant-related factors were compared between groups classified 
by race. Cohorts were compared using Chi-square and Kruskal-Wallis tests for categorical 
variables and continuous variables, respectively. Cumulative incidences for GVHD, relapse, 
and non-relapse mortality were calculated using the cumulative incidence function to 
account for competing risks.[18] Competing events were death without relapse for relapse, 
relapse for non-relapse mortality, and death without GVHD for acute and chronic GVHD. 
Gray’s test was employed to evaluate the overall differences among cumulative incidence 
functions.[19] Leukemia-free and overall survival rates were estimated using the Kaplan-
Meier estimator. The log-rank test was used to compare survival experience among different 
groups. Ninety-five percentage CIs for true survival probabilities were calculated based on 
arcsine-square root transformation. The impact of race and stem cell source on outcomes of 
interest was evaluated using the Cox proportional hazards model. The assumption of 
proportional hazards for each covariate in the Cox model was tested using time-dependent 
covariates. When the test indicated differential effects over time (non-proportional hazards), 
models were constructed to break the post-transplant time course into two periods. The 
maximized partial likelihood method was used to determine the most appropriate 
breakpoint. The proportionality assumptions were then further tested. A stepwise selection 
procedure was used to identify covariates associated with outcomes. The main effects of this 
study - race (North American Caucasian vs. Japanese) and graft source (BM vs. PBSC) - 
were included in all steps of model building. Other variables considered included recipient 
age group, recipient sex, KPS, disease status prior to the transplantation, donor age, donor-
recipient cytomegalovirus (CMV) status, donor-recipient sex match, donor-recipient ABO 
blood group match, conditioning regimen, GVHD prophylaxis, and year of transplantation. 
Covariates that reached a significance level of 0.05 were included in the final models. An 
interaction test was used to determine whether the effects of graft source on transplant 
outcomes were different between the two groups. If the interaction was statistically 
significant, the main effects were combined into one main effect variable (graft source by 
race) in the final models. Otherwise, graft source and race were included as two independent 
main effects in the final models. Any potential interactions between main effect term and 
variables in the final model were evaluated. SAS 9.3 (SAS Inc., Cary, NC) statistical 
software was used for all analyses.
RESULTS
Patient characteristics
Table 1 shows patient, donor, and transplant characteristics. BM was used in 13% and 53% 
of the Caucasian and Japanese patients, respectively. Japanese patients were more likely to 
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be young, have better KPS scores, have early stages of ALL, have both donor and recipient 
CMV seropositivity, receive transplants from ABO mismatched donors, receive a 
cyclophosphamide + TBI regimen, receive cyclosporine-based prophylaxis, and receive a 
transplant after 2006. Majority of North American Caucasian is American and only 3% is 
Canadian.
Interaction between race and graft source
An interaction test was used to determine whether the effects of graft source on transplant 
outcomes were different between the two populations. In multivariate analysis, the 
interaction term between race and graft source was not significant in any of the models for 
all outcomes analyzed, which indicated that the impact of race on outcomes did not differ 
according to graft source (Supplemental Table 1). Therefore, graft source and race were 
treated as two independent main effects analyzing all outcomes.
Acute and chronic GVHD
The unadjusted cumulative incidence of grades II–IV acute GVHD at 100 days post 
transplantation was 31% (95% CI, 29%–34%) and 31% (95% CI, 28%–33%) in Caucasian 
and Japanese patients, respectively (Gray’s test, P=0.11); the incidence for grades III–IV 
acute GVHD post transplantation was 14% (95% CI, 12%–16%) and 8% (95% CI, 7%–
10%) in Caucasian and Japanese patients, respectively (Gray’s test, P<0.001). In 
multivariate analysis, the risk of grades II–IV acute GVHD was comparable between both 
groups (hazard ratio [HR] 1.04, 95% CI 0.87–1.24, P=0.677), whereas the risk of grades III–
IV acute GVHD was significantly lower in Japanese patients compared to Caucasians (HR 
0.75, 95% CI 0.57–0.99, P=0.042) (Table 2). The risk of chronic GVHD was significantly 
lower in Japanese compared to Caucasian patients (within 12 months after transplantation, 
HR 0.85, 95% CI 0.73–0.99, P = 0.037; 12 months or more after transplantation, HR 0.33, 
95% CI 0.21–0.51, P < 0.001). The unadjusted cumulative incidences of GVHD stratified by 
stem cell sources are shown in Supplemental Table 2. Adjusted cumulative incidence curves 
are shown in Figure 1.
Relapse and non-relapse mortality
The unadjusted cumulative incidence of relapse 3 years post transplantation was 33% (95% 
CI, 30%–35%) and 25% (95% CI, 23%–28%) in Caucasian and Japanese patients, 
respectively (Gray’s test, P<0.001); the incidence of non-relapse mortality post 
transplantation was 18% (95% CI, 16%–20%) and 13% (95% CI, 11%–15%), respectively 
(Gray’s test, P<0.001). In multivariate analysis, the risks of relapse and non-relapse 
mortality were significantly lower in Japanese than in Caucasians patients (relapse; HR 0.73, 
95% CI 0.61–0.87, P<0.001, non-relapse mortality; HR 0.72, 95% CI 0.55–0.93, P=0.012, 
Table 3). The adjusted cumulative incidence curves are shown in Figure 2.
Disease-free and overall survival
The unadjusted probability of disease-free survival 3 years post transplantation was 49% 
(95% CI, 46%–52%) and 62% (95% CI, 59%–65%) in Caucasian and Japanese patients, 
respectively (log-rank test, P<0.001), and 57% (95% CI, 54%–60%) and 68% (95% CI, 
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65%–71%) for overall survival post transplantation, respectively (log-rank test, P<0.001). In 
multivariate analysis, the risks of death or relapse and overall mortality were significantly 
lower in Japanese than Caucasian patients (death or relapse; HR 0.78, 95% CI 0.68–0.89, 
P<0.001, overall mortality; HR 0.72, 95% CI 0.60–0.85, P<0.001, Table 3). Adjusted 
survival curves are shown in Figure 3.
DISCUSSION
Contrary to our initial hypothesis, the impact of race on acute GVHD did not differ 
according to BM or PBSC graft. Irrespective of graft source, the risk of severe acute GVHD 
was lower in Japanese patients. Although the main determinant of GVHD occurrence is the 
major histocompatibility antigen,[20] occurrence of GVHD in transplantation from an HLA-
identical sibling indicates that non-HLA gene polymorphisms play an important role in 
GVHD.[21] Candidate gene studies have shown that various gene polymorphisms in 
recipients and donors are associated with GVHD.[21] Furthermore, the genome-wide 
association study confirms that some gene polymorphisms such as IL-2, IL-6, CTLA4, 
HPSE, and MTHFR are responsible for GVHD.[22] Such polymorphisms could be 
responsible for racial differences in GVHD occurrence. The relative homogeneity of minor 
histocompatibility antigens among Japanese individuals may also explain the reduced 
GVHD incidence in this population. Differences in frequencies of HLA antigens or 
haplotypes between the two populations may also contribute to differences in GVHD 
incidence.[2] Specific haplotypes have been associated with risk of acute GVHD.[23] The 
strength of T cell activation caused by minor histocompatibility antigens may differ by 
haplotype and major histocompatibility complex. Notably, our study showed that differences 
between the two populations were not affected by use of PBSC, which contains larger T cell 
populations and smaller non-hematopoietic populations than BM.
Unmeasured factors such as socioeconomic, environmental, or practice differences may also 
be responsible for outcome differences after allogeneic transplantation in the two 
populations. Analysis of unrelated myeloablative transplantation using the CIBMTR data 
indicated that lower income is associated with higher rates of non-relapse and overall 
mortality,[24] highlighting the importance of socioeconomic factors on transplant outcomes. 
Health insurance systems also differ; health insurance is privately purchased insurance or 
social welfare insurance in the U.S., while Japan offers universal health insurance coverage. 
This difference could affect access to medical care and medicine availability, including 
recently approved or unapproved treatments. The difficulty of adjusting for these factors 
limits the interpretation of our findings. Comparison of transplant outcomes of Japanese 
populations living outside Japan to those living in Japan could help evaluate these effects, 
although such an analysis is unlikely to be feasible due to the small sample size. Missing or 
insufficient data is also needs to be considered in interpreting the result. Missing data in 
CMV serostatus in the Japanese populations is not negligible and may have influenced the 
findings.
The lower risk of non-relapse mortality in the Japanese patients compared to the Caucasian 
patients partly reflects the lower incidence of grades III–IV acute GVHD among the 
Japanese patients. Interestingly, even lower risk of relapse was also observed in the 
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Japanese. This lower risk was previously noted in unrelated BMT and PBSCT.[25] Racial 
differences in leukemic cell susceptibility to chemotherapeutic agents may play a role in 
relapse. Yang et al. showed that genetic characteristics associated with Native American 
ancestry affect the risk of ALL relapse.[26] Furthermore, a particular SNP associated with 
drug resistance in vitro is also highly associated with relapse.[26] Genetic differences related 
to relapse between the two populations is worthy of further evaluation in future studies. 
Another possibility is differences in graft-versus-leukemia effects. Unlike previous findings 
in cohorts receiving transplantations between 1990 and 1999,[2] we did not observe any 
difference in the risk of grades II–IV acute GVHD between the two cohorts receiving 
transplantations between 2000 and 2011. This may be partly because Japanese physicians 
tended to weaken or taper GVHD prophylaxis earlier than before, expecting to enhance 
graft-versus-leukemia effects, since the GVHD incidence was very low in an HLA-matched 
sibling BMT among Japanese patients.[1] Alternatively, GVHD prophylaxis might have 
been intensified in the decade for Caucasian patients. Although cyclosporine has still been 
mainly used as GVHD prophylaxis for matched sibling transplantation in Japanese patients, 
tacrolimus-based GVHD prophylaxis has replaced this in Caucasian patients. Although the 
type of GVHD prophylaxis did not affect acute GVHD in the present study, such a change 
of practice may decrease the incidence of acute GVHD and the associated graft-versus-
leukemia effects in Caucasian patients. The graft-versus-leukemia effects need to be 
interpreted according to each disease. In the present study, there was no interaction between 
race or stem cell source and disease in the multivariate analysis for relapse, which suggested 
that the impact of race on relapse was independent of disease type. Finally, although we 
included only early and intermediate disease status, i.e. AML and ALL in 1st or 2nd 
complete remission and CML in complete remission, or chronic or accelerated phase, lack of 
information on the cytogenetic and molecular risks in each disease may limit the 
interpretation of this study.
Contrary to the BMT and PBSCT findings, there was no difference in acute GVHD 
incidence or overall mortality after pediatric unrelated cord blood transplantation between 
Japanese and U.S. Caucasian patients.[27] In addition to qualitative and quantitative 
differences in the composition of BM, PBSC, and unrelated cord blood grafts, this may be 
partly because advantages associated with shared minor histocompatibility antigens in the 
more homogenous Japanese population may be weakened in unrelated cord blood 
transplantation with multiple major histocompatibility antigen mismatches.
In conclusion, irrespective of graft source, the risk of severe acute GVHD in this study was 
lower in Japanese patients, which resulted in a lower risk of non-relapse mortality. The 
difference in the incidence of grades III–IV acute GVHD may have been due to racial 
differences in non-HLA gene polymorphisms and minor histocompatibility antigens 
presented by specific major histocompatibility antigens. However, this could also be 
affected by socioeconomic or environmental factors or differences between practices. 
Although this study cannot separately evaluate genetic and non-genetic effects, it highlights 
the importance of considering racial differences not only in HLA-matched sibling BMT but 
also in PBSCT, particularly when interpreting and applying findings from different racial 
populations.
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The impact of race on transplant outcomes was independent of graft source.
The risk of severe acute GVHD was lower in Japanese than in Caucasian patients.
Lower risk of acute GVHD resulted in lower risk of non-relapse mortality in Japanese.
The risk of relapse was lower in Japanese than in Caucasian patients.
Overall survival was higher in Japanese than in Caucasian patients.
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Adjusted cumulative incidence of grades II–IV (A) or III–IV acute GVHD (B) and chronic 
GVHD (C)
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Adjusted cumulative incidence of relapse (A) and non-relapse mortality (B)
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Adjusted probability of disease-free (A) and overall survival (B)
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Table 1





(n = 1352) P-value
Median recipient age at transplant (range), years 45 (18–59) 38 (18–59) <0.001
Recipient age at transplant, years <0.001
  18–29 229 (18) 342 (25)
  30–39 230 (18) 414 (31)
  40–49 417 (32) 354 (26)
  50–59 424 (33) 242 (18)
Recipient sex 0.82
  Male 729 (56) 764 (57)
  Female 571 (44) 588 (43)
Karnofsky score <0.001
  90–100% 872 (67) 1138 (84)
  < 90% 380 (29) 208 (15)
  Missing 48 (4) 6 (<1)
Stem cell source <0.001
  Bone marrow 165 (13) 717 (53)
  Peripheral blood 1135 (87) 635 (47)
Disease risk prior to transplant
  AML 0.26
    Early 565 (43) 506 (37)
    Intermediate 174 (13) 179 (13)
  ALL <0.001
    Early 238 (18) 472 (35)
    Intermediate 68 (5) 57 (4)
  CML 0.31
    Early 179 (14) 90 (7)
    Intermediate 76 (6) 48 (4)
Donor age, median 44 (8–75) 38 (11–67) <0.001
Donor-recipient CMV status <0.001
  +/+ 384 (30) 654 (48)
  +/− 159 (12) 110 (8)
  −/+ 334 (26) 108 (8)
  −/− 390 (30) 95 (7)
  Missing 33 (3) 385 (28)
Donor-recipient sex match 0.02
  Male-Male 421 (32) 413 (31)
  Male-Female 311 (24) 310 (23)
  Female-Male 308 (24) 346 (26)
  Female-Female 260 (20) 273 (20)
  Missing 0 10 (<1)


















(n = 1352) P-value
Donor-recipient ABO match <0.001
  Match 854 (66) 750 (55)
  Minor mismatch 197 (15) 211 (16)
  Major mismatch 176 (14) 202 (15)
  Bidirectional mismatch 48 (4) 86 (6)
  Missing 25 (2) 103 (8)
Conditioning regimen <0.001
  Cy + TBI 566 (44) 931 (69)
  Other TBI regimen 132 (10) 98 (7)
  Bu + Cy +/− other 466 (36) 258 (19)
  Other non TBI regimen 136 (10) 65 (5)
GVHD prophylaxis <0.001
  TAC + MTX 642 (49) 84 (6)
  Other TAC based prophylaxis 238 (18) 7 (<1)
  CSA + MTX 343 (26) 1197 (89)
  Other CSA based prophylaxis 77 (6) 64 (5)
Year of transplant 0.013
  2000–2005 498 (38) 455 (34)
  2006–2011 802 (62) 897 (66)
Country
  United States 1262 (97) 0
  Canada 38 (3) 0
  Japan 0 1352 (100)
Median follow-up of survivors (range), months 52 (3–149) 49 (1–151)
Abbreviations: AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CMV, 
cytomegalovirus; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; TAC, tacrolimus; MTX, methotrexate; CSA, cyclosporine.
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Table 2
Multivariate analyses of grades II–IV or III–IV acute GVHD and chronic GVHD
Number HR P value
Grades II–IV acute GVHD*
  Race Caucasian 1298 1.00 Reference
Japanese 1343 1.04 (0.87–1.24) 0.677
  Graft BM 876 1.00 Reference
PBSC 1765 1.20 (1.02–1.42) 0.029
Grades III–IV acute GVHD†
  Race Caucasian 1299 1.00 Reference
Japanese 1342 0.75 (0.57–0.99) 0.042
  Graft BM 877 1.00 Reference
PBSC 1764 1.57 (1.16–2.14) 0.004
Chronic GVHD††
  Race Caucasian 1267 1.00 Reference
Japanese (< 12 mos after HCT) 1324 0.85 (0.73–0.99) 0.037
Japanese (≥ 12 mos after HCT) 0.33 (0.21–0.51) <0.001
  Graft BM 866 1.00 Reference
PBSC 1725 1.66 (1.45–1.91) <0.001
BM, bone marrow; PBSC, peripheral blood stem cell; mos, months; HCT, hematopoietic cell transplantation
*
Other significant variables used for adjustment were donor age and CMV match.
†
Other significant variables used for adjustment were donor age and disease.
††
Other significant variables used for adjustment were sex match, GVHD prophylaxis and year of transplant.
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Table 3
Multivariate analyses of relapse, non-relapse mortality, death or relapse, and overall mortality
Number HR P value
Relapse*
  Race Caucasian 1281 1.00 Reference
Japanese 1313 0.73 (0.61–0.87) <0.001
  Graft BM 861 1.00 Reference
PBSC 1733 1.00 (0.84–1.19) 0.999
Non-relapse mortality**
  Race Caucasian 1281 1.00 Reference
Japanese 1323 0.72 (0.55–0.93) 0.012
  Graft BM 862 1.00 Reference
PBSC 1742 1.35 (1.07–1.71) 0.012
Death or relapse†
  Race Caucasian 1281 1.00 Reference
Japanese 1323 0.78 (0.68–0.89) <0.001
  Graft BM 862 1.00 Reference
PBSC 1742 1.09 (0.94–1.25) 0.253
Overall mortality††
  Race Caucasian 1300 1.00 Reference
Japanese 1352 0.72 (0.60–0.85) <0.001
  Graft BM 882 1.00 Reference
PBSC 1770 1.18 (1.01–1.37) 0.038
BM, bone marrow; PBSC, peripheral blood stem cell
*
Other significant variables used for adjustment were ABO match, conditioning, disease, sex match, and KPS.
**
Other significant variables used for adjustment were recipient age, conditioning, sex match, GVHD prophylaxis, KPS, year of transplant, and 
disease.
†
Other significant variables used for adjustment were recipient age, disease, KPS, and recipient sex.
††
Other significant variables used for adjustment were recipient age, conditioning, disease, GVHD prophylaxis, KPS, recipient sex, and year of 
transplant.
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